Healthcare M&A and New FTC and DOJ Merger Guidelines: What’s Next for Your Transactions? - McDermott Will & Emery

Healthcare M&A and New FTC and DOJ Merger Guidelines: What’s Next for Your Transactions?

Overview


DOWNLOAD THE TAKEAWAYS 

The FTC and DOJ’s proposed revised merger guidelines signal the Biden administration’s continued aggressive antitrust enforcement stance even as healthcare industry participants continue to seek to overcome the effects of inflation, a difficult capital market cycle and overall challenging operating environment.

Join McDermott Health Antitrust partners Ashley Fischer and Stephen Wu, and Kaufman Hall M&A practice leader Anu Singh for a deep dive into the implications of the FTC and DOJ’s revised merger guidelines for healthcare industry M&A, including:

  • How the revised merger guidelines differ from the current guidelines
  • What they mean for healthcare organizations and those doing deals in the healthcare space
  • What organizations can do to navigate a more complex antitrust environment for future M&A transactions in the health industry

SPEAKERS


Anu Singh, Managing Director, Practice Leader, Partnerships, Mergers & Acquisitions, Kaufman Hall

Dig Deeper

New York, NY / McDermott Event / October 17, 2024

Save the Date | HPE NYC 2024

London, United Kingdom / McDermott Event / September 19, 2024

HPE Europe 2024

Chicago, IL / Speaking Engagements / May 14, 2024

Modern Healthcare Digital Health Summit: Patients and Trust

Nashville, TN / McDermott Event / May 17, 2024

Value-Based Care Symposium 2024

Nashville, TN / McDermott Event / May 15-16, 2024

Physician Practice Management and ASC Symposium 2024

Webinar / McDermott Webinar / June 4, 2024

AI Governance Essentials for Hospitals and Health Systems

Get In Touch